Analysts at Cantor Fitzgerald began coverage on shares of Medmen Enterprises (OTCMKTS:MMNFF) in a research note issued on Thursday, MarketBeat reports. The brokerage set a “neutral” rating on the stock.
A number of other equities research analysts have also recently commented on MMNFF. Cowen upgraded shares of Medmen Enterprises from an “underperform” rating to a “market perform” rating and set a $0.75 price target on the stock in a report on Tuesday, December 17th. Seaport Global Securities reiterated a “buy” rating and set a $4.00 price target on shares of Medmen Enterprises in a report on Monday, December 9th.
OTCMKTS:MMNFF opened at $0.30 on Thursday. The company’s 50 day moving average price is $0.47 and its 200-day moving average price is $1.11. Medmen Enterprises has a 52 week low of $0.28 and a 52 week high of $3.51.
MedMen Enterprises Inc, together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, and distributes, and retails recreational and medicinal cannabis. As of November 1, 2018, it had licenses for 69 retail stores; and 17 cultivation and production facilities across 12 states.
Recommended Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Medmen Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medmen Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.